Biopharma Deal Making Round Up for 2023
A look at the top ten deals in the biopharma industry in 2023.
In the past year, mergers and acquisitions (M&A) in the biopharma sector have made a notable resurgence. Following a cautious 2022, cash on hand, efforts invested in business development, and strategic pipeline portfolio assessments have yielded results. Syneos Health Consulting has compiled the top global biopharma deals as well as the top U.S. initial public offerings (IPOs) to provide a snapshot for 2023. As we move forward, we will closely monitor emerging trends in dealmaking, both within big pharma and biotech. You'll have an opportunity to discuss deal making support with our Consulting Team at Biotech Showcase 2024.
Stay tuned for our forthcoming Dealmakers' Intentions Survey – this annual survey offers a comprehensive overview of biopharmaceutical dealmakers' expectations for deal activity in the upcoming year.
Related Content
Looking for exclusive insight?
